Brookline initiates Revolution Medicines stock with buy rating

Brookline Capital Markets has started tracking Revolution Medicines Inc. (RVMD) on the NASDAQ with a positive outlook, assigning the stock a "buy" rating and setting a price target of $318. The company's shares are currently valued at $204.97, marking a remarkable 367% increase over the past year, with estimates ranging from $179 to $320.

Revolution Medicines specializes in developing targeted therapies to combat cancers with RAS-addicted proteins. Their pipeline features RAS(ON) inhibitors aimed at inhibiting various RAS protein variants. The firm recently approved their first product, Rasonque (daraxonrasib), for pancreatic ductal adenocarcinoma, and anticipates further expansion into lung cancer within the next few years.

Brookline projects Revolution Medicines' revenue to reach $151 million by 2026, surging to $1.3 billion by 2027 and $59.5 billion by 2033. The company is currently operating with negative cash flow through 2026 but is projected to become cash flow positive in 2027. As of June 30, 2026, Revolution Medicines held approximately $3.9 billion in cash and $1.2 billion in debt, demonstrating a strong liquidity position with a current ratio of 11.38.

Pro Analysis indicates the stock is presently overvalued, but the firm remains optimistic about the company's prospects, supported by its positive cash flow outlook.